羧酸酯酶
前药
化学
作用机理
药理学
生物信息学
药品
酶
生物化学
重组DNA
丝氨酸水解酶
对接(动物)
抗病毒药物
丝氨酸
活动站点
水解酶
基质(水族馆)
催化三位一体
机制(生物学)
酶抑制剂
药代动力学
HEK 293细胞
结合位点
作者
Abhinav Pentyala,Sylvie E. Kandel,Jed Noah Lampe
标识
DOI:10.1016/j.dmd.2025.100158
摘要
COVID-19 remains a significant health threat, particularly to people over the age of 65 with existing comorbidities like diabetes, hypertension, cancer, and viral infections. Despite expedited drug approvals, drug-drug interaction profiles for COVID-19 antiviral drugs have not yet been completely defined. The antiviral drugs remdesivir and molnupiravir are ester prodrugs with carboxylesterases (CES) playing a critical role in their bioactivation. In this study, we investigated the effect of COVID-19 antiviral drugs on CES hydrolysis activity. Of the 3 drugs tested, remdesivir inhibited 50% of CES2 activity in a nanomolar concentration range. Furthermore, time-dependent inhibition of CES2 activity by remdesivir was identified with an IC 50 shift of nearly 3-fold from 0.188 μ M after 5-minute preincubation to 0.068 μ M following 40-minute preincubation. Remdesivir inactivation of CES2 was characterized by a k inact /K I value of 1.6 × 10 3 M −1 .s −1 . Through equilibrium dialysis and substrate protection experiments, we were able to further substantiate previous findings of the irreversible CES2 inhibition by remdesivir. Finally, in silico docking analysis of remdesivir to CES2 supported the proposed mechanism for covalent modification of the CES2 active site involving the catalytic triad serine via the phosphate group of remdesivir. Significance Statement This study provides insights into human carboxylesterase inhibition by COVID-19 drugs and these findings demonstrate the underlying inhibition mechanism by remdesivir of recombinant human carboxylesterase 2.
科研通智能强力驱动
Strongly Powered by AbleSci AI